ProMIS Neurosciences Inc. (PMN)

ProMIS Neurosciences, Inc.'s stock price decreased by 22.05% from May 7, 2025, to May 6, 2026, with a 52-week trading range between $6.27 and $39.75. Key events include completing enrollment for the PRECISE-AD Phase 1b clinical trial in December 2025, announcing a private placement financing of up to $175 million in January 2026, closing a private placement for $75.5 million in February 2026, announcing Full Year 2025 Financial Results in March 2026, presenting data on ALS and Parkinson's Disease programs at the AD/PD™ conference in March 2026, participating in the Bloom Burton & Co. Healthcare Investor Conference in April 2026, and scheduling its 2026 Annual Meeting of Stockholders in May 2026. Upcoming catalysts include the expected blinded 6-month top-line data from the PRECISE-AD study in mid-2026, a blinded interim analysis anticipated in early Q3 2026, and 12-month top-line data expected in early 2027.

ProMIS Neurosciences, Inc. does not currently have commercialized products or services, so there is no discernible demand seasonality.

ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines for neurodegenerative and misfolded protein diseases. The company utilizes its EpiSelect™ target discovery engine to identify Disease Specific Epitopes (DSEs) on misfolded proteins, targeting diseases like Alzheimer's, ALS, FTD, MSA, and Parkinson's. Its major product candidates include PMN310 for Alzheimer's disease, which has completed a Phase 1a clinical study and is in a Phase 1b trial, PMN267 for ALS, and PMN442 for MSA. The company is also developing other therapeutic antibodies, vaccines, and diagnostics.

ProMIS Neurosciences, Inc. has offices in Cambridge, Massachusetts, USA, and Toronto, Ontario, Canada.

ProMIS Neurosciences' reputation has been shaped by positive developments and financial concerns. Positive events include exceeding target enrollment in the PRECISE-AD trial, reporting reduced ARIA risk for PMN310, announcing positive top-line data from the Phase 1a trial of PMN310, and presenting preclinical data at international conferences. Challenges include having less than one year of cash runway as of November 2025, declining earnings, unprofitability with revenue less than US$1 million, substantial shareholder dilution, and a Nasdaq non-compliance notice in July 2024.

ProMIS Neurosciences, Inc. has significant institutional ownership, with 17 institutional owners and shareholders holding 263,399 shares, representing approximately 50.13% to 67.1% of the company's stock. Major institutional owners include Ally Bridge Group, Sphera Funds Management Ltd., and UBS Group AG. Individual investors hold about 4.5% of the shares, and Jeremy M. Sclar is a major shareholder.